JNJ
Johnson & Johnson: a strengthening business near record highs, with almost no upside left to consensus
A 3-of-4 Financial Scorecard, 9.9% quarterly revenue growth and the best timing signals in this group (2-of-3). But the stock is just 7% below its high, valuation scores 1-of-4 sensible, and 21 analysts' $236.21 average target sits under 1% above the price, with 52% rating it only Hold. Current price: $234.20.
pharmamedtechdividend-king